Evidence map›Paper›PMID 26366275›Full record

ArticleKorean journal of urology2015

Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer.

Jaeyoon Jung, Chunwoo Lee, Chanwoo Lee, Taekmin Kwon, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Korean journal of urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jaeyoon JungDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Chunwoo LeeDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Chanwoo LeeDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Taekmin KwonDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Dalsan YouDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
In Gab JeongDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jun Hyuk HongDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hanjong AhnDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Choung-Soo KimDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo determine whether statin use delays the development of castration-resistant prostate cancer (CRPC) in patients with metastatic prostate cancer treated with androgen deprivation therapy (ADT). MATERIALS AND

methodsA total of 171 patients with metastatic prostate cancer at the time of diagnosis who were treated with ADT between January 1997 and December 2013 were retrospectively analyzed. The patients were classified into two groups: the nonstatin use group (A group) and the statin use group (B group). Multivariate analysis was performed on statin use and other factors considered likely to have an effect on the time to progression to CRPC.

resultsThe mean patient age was 67.1±9.1 years, and the mean follow-up period was 52 months. The mean initial prostate-specific antigen (PSA) level was 537 ng/mL. Of the 171 patients, 125 (73%) were in group A and 46 (27%) were in group B. The time to progression to CRPC was 22.7 months in group A and 30.5 months in group B, and this difference was significant (p=0.032). Blood cholesterol and initial PSA levels did not differ significantly according to the time to progression to CRPC (p=0.288, p=0.198). Multivariate analysis using the Cox regression method showed that not having diabetes (p=0.037) and using a statin (p=0.045) significantly increased the odds ratio of a longer progression to CRPC.

conclusionsStatin use in metastatic prostate cancer patients appears to delay the progression to CRPC. Large-scale, long-term follow-up studies are needed to validate this finding.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overAndrogen AntagonistsAntineoplastic Combined Chemotherapy ProtocolsBody Mass IndexDiabetes MellitusDisease ProgressionHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedNeoplasm GradingProstatic Neoplasms, Castration-ResistantProtective FactorsAndrogen AntagonistsHydroxymethylglutaryl-CoA Reductase InhibitorsCastration-resistant prostatic neoplasmsHydroxymethylglutaryl-CoA reductatse inhibitorsMetastatic prostatic neoplasm

Identifiers

PMID26366275
PMCPMC4565897

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.